DIOSYNTH
LIVE

Serial Number

79199948

Owner

FUJIFILM CORPORATION

Attorney

Mainak H. Mehta

Filing Date

Oct 2, 2015

Add to watchlist:

No watchlists yet
View on USPTO

DIOSYNTH Trademark

Serial Number: 79199948 • Registration: 5273482

DIOSYNTH is a trademark filed by FUJIFILM CORPORATION on October 2, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

FUJIFILM CORPORATION (515 trademarks)

26-30, NISHIAZABU 2-CHOME, MINATO-KU
TOKYO , JP

Entity Type: 03

Trademark Details

Filing Date

October 2, 2015

Registration Date

August 29, 2017

Published for Opposition

June 13, 2017

Goods & Services

Services of biotechnical, chemical and pharmacological laboratories, namely, scientific and technological research relating to the production of chemicals and biotechnological products for use in preparing pharmaceutical and veterinary preparations; scientific and technological research relating to the production of chemicals and biotechnological products for use in preparing pharmaceutical and veterinary preparations, and scientific consultation related thereto; scientific research, namely, carrying out early evaluations in the field of new medicines; development of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation and research in the field of new product development in the pharmaceutical and health care industries; scientific analysis and research, namely, evaluation of pharmaceutical products; research and development in the pharmaceutical field; scientific research and development with regard to medicines; product development, namely, preparation of pharmaceutical test products; advisory services relating to scientific research, development and analyses of medicines; development of new technologies in the biotechnology sector; providing information with regard to scientific research in the field of biochemistry and biotechnology; scientific research, including in the medical sector

Custom manufacture of pharmaceuticals

[ Medicines and pharmaceutical products, including medicines and pharmaceutical products for veterinary use, namely, medicines and pharmaceutical preparations for the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, urological, urogenital disorders and, gastrointestinal disorders, musculoskeletal disorders, allergies, diabetes, hypertension, erectile dysfunction, sexual dysfunction, stroke, cancer, migraines, pain, obesity, inflammation and inflammatory disease, respiratory and infectious diseases, immunological, bacterial, viral and fungal disorders, mental illness, depression, psychosis, bone and mineral diseases, infertility, menopausal complaints, hormone deficiencies, and sleep disorders; pharmaceutical preparations, namely, preparations to lower cholesterol, smoking cessation preparations, tissue and skin repair preparations, dermatological preparations, and gynecological preparations, contraceptives, muscle relaxants, muscle relaxant antagonists; biotechnological preparations for medical use, namely use in gene therapy; biochemicals, namely, biochemical preparations for medical use, namely use in gene therapy; genetic material, namely, genetically engineered tissue, for transplant purposes for genetic cell therapy ]

[ Chemical preparations and substances for manufacturing of pharmaceutical products, namely, chemical preparations and substances for manufacturing pharmaceutical products for veterinary applications; chemical additives for manufacturing medicines; chemicals for manufacturing cosmetics, skin cleansers and medicines; chemical preservatives for pharmaceutical preparations; biochemicals, namely, polypeptides, recombinant proteins, organic peptide substrates and monoclonal antibodies for producing products for genetic pharmacology ]

Filing History

PARTIAL INVALIDATION PROCESSED BY THE IB
Jan 15, 2026 INNP
GENERIC MADRID TRANSACTION SENT TO IB
Dec 8, 2025 XXSS
GENERIC MADRID TRANSACTION CREATED
Dec 8, 2025 XXCR
INTERNATIONAL REGISTRATION RENEWED
Oct 9, 2025 RNWL
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jun 30, 2025 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Oct 31, 2024 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Oct 31, 2024 C75P
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Oct 12, 2024 EROP
POST REGISTRATION ACTION MAILED - SEC. 71 & 15
May 16, 2024 PR75
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 22, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
Aug 22, 2023 ES75
NEW REPRESENTATIVE AT IB RECEIVED
Jan 13, 2023 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Aug 29, 2022 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 6, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 13, 2017 FICS
FINAL DISPOSITION PROCESSED
Dec 13, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 29, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Aug 29, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 13, 2017 NPUB
PUBLISHED FOR OPPOSITION
Jun 13, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 24, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 2, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 25, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 24, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 24, 2017 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 18, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 18, 2017 REAP
REFUSAL PROCESSED BY IB
Feb 18, 2017 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 24, 2017 RFCS
REFUSAL PROCESSED BY MPU
Jan 24, 2017 RFRR
APPLICATION FILING RECEIPT MAILED
Jan 21, 2017 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 19, 2017 RFCR
NON-FINAL ACTION WRITTEN
Jan 18, 2017 CNRT
ASSIGNED TO EXAMINER
Jan 17, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 17, 2017 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 13, 2017 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 5, 2017 REPR